PharmaCyte Biotech (PMCB) Short Interest Ratio & Short Volume $1.81 -0.06 (-3.21%) (As of 10/31/2024 ET) Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends PharmaCyte Biotech Short Interest DataPharmaCyte Biotech (PMCB) has a short interest of 21,100 shares, representing 0.30% of the float (the number of shares available for trading by the public). This marks a 13.44% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.0, indicating that it would take 1.0 days of the average trading volume of 25,166 shares to cover all short positions.Current Short Interest21,100 sharesPrevious Short Interest18,600 sharesChange Vs. Previous Month+13.44%Dollar Volume Sold Short$36,292.00Short Interest Ratio1.0 Days to CoverLast Record DateOctober 15, 2024Outstanding Shares7,679,000 sharesFloat Size7,080,000 sharesShort Percent of Float0.30%Today's Trading Volume19,627 sharesAverage Trading Volume25,166 sharesToday's Volume Vs. Average78% Short Selling PharmaCyte Biotech? Sign up to receive the latest short interest report for PharmaCyte Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPMCB Short Interest Over TimePMCB Days to Cover Over TimePMCB Percentage of Float Shorted Over Time Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… PharmaCyte Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/202421,100 shares $36,292.00 +13.4%0.3%1 $1.72 9/30/202418,600 shares $35,526.00 +8.1%0.3%0.9 $1.91 9/15/202417,200 shares $32,680.00 +152.9%0.2%1 $1.90 8/31/20246,800 shares $10,404.00 -38.7%0.1%0.4 $1.53 8/15/202411,100 shares $20,868.00 +200.0%0.2%0.6 $1.88 7/31/20243,700 shares $7,252.00 -74.8%0.1%0.2 $1.96 Get the Latest News and Ratings for PMCB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. 7/15/202414,700 shares $30,282.00 -40.7%0.2%0.9 $2.06 6/30/202424,800 shares $48,608.00 -31.1%0.3%1.3 $1.96 6/15/202436,000 shares $78,120.00 +718.2%0.5%1.4 $2.17 5/31/20244,400 shares $8,624.00 -66.7%0.1%0.2 $1.96 5/15/202413,200 shares $27,588.00 +1.5%0.2%0.6 $2.09 4/30/202413,000 shares $27,560.00 -28.6%0.2%0.5 $2.12 4/15/202418,200 shares $38,402.00 -60.2%0.2%0.7 $2.11 3/31/202445,700 shares $108,309.00 +501.3%0.6%1.8 $2.37 3/15/20247,600 shares $14,820.00 -68.7%0.1%0.3 $1.95 2/29/202424,300 shares $51,030.00 -4.3%0.3%1.6 $2.10 2/15/202425,400 shares $53,086.00 -19.4%0.4%1.6 $2.09 1/31/202431,500 shares $68,985.00 +18.9%0.4%2 $2.19 1/15/202426,500 shares $59,625.00 -14.8%0.4%1.5 $2.25 12/31/202331,100 shares $67,176.00 +15.2%0.5%1.8 $2.16 12/15/202327,000 shares $58,050.00 +2.7%0.4%1.5 $2.15 11/30/202326,300 shares $59,438.00 -9.6%0.4%1.4 $2.26 11/15/202329,100 shares $59,364.00 -12.6%0.4%1.5 $2.04 10/31/202333,300 shares $70,596.00 -17.4%0.5%1.6 $2.12 10/15/202340,300 shares $84,227.00 -12.2%0.6%1.9 $2.09 9/30/202345,900 shares $96,390.00 -27.8%0.7%2.1 $2.10 9/15/202363,600 shares $159,000.00 +27.0%0.9%3 $2.50 8/31/202350,100 shares $122,745.00 -4.0%0.6%1.9 $2.45 6/30/202139,300 shares $424.44 +48.9%N/A0 $0.01 6/15/202126,400 shares $298.32 -27.7%N/A0 $0.01 5/28/202136,500 shares $463.55 -69.0%N/A0 $0.01 5/14/2021117,600 shares $1,481.76 +113.4%N/A0 $0.01 4/30/202155,100 shares $936.70 -72.2%N/A0 $0.02 4/15/2021198,000 shares $3,245.22 +11.1%N/A0 $0.02 3/31/2021178,200 shares $3,073.95 +11.0%N/A0 $0.02 3/15/2021160,500 shares $3,370.50 +817.1%N/A0 $0.02 2/26/202117,500 shares $507.50 -93.3%N/A0 $0.03 2/12/2021260,800 shares $4,824.80 +327.5%N/A0 $0.02 1/29/202161,000 shares $1,037.00 +42.9%N/A0 $0.02 1/15/202128,200 shares $383.52 -69.7%N/A0 $0.01The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, 12/31/202041,700 shares $271.05 +47.9%N/A0 $0.01 12/15/202028,200 shares $155.10 -69.7%N/A0 $0.01 11/30/202093,200 shares $559.20 +486.2%N/A0 $0.01 11/15/202015,900 shares $108.12 No ChangeN/A0 $0.01 10/30/202015,900 shares $141.51 +13.6%N/A0 $0.01 10/15/202014,000 shares $131.60 -74.0%N/A0 $0.01 9/30/202053,900 shares $916.30 +20.0%N/A0 $0.02 9/15/202044,900 shares $493.90 -58.9%N/A0 $0.01 8/31/2020109,300 shares $1,300.67 +680.7%N/A0 $0.01 8/14/202014,000 shares $196.00 -95.6%N/A0 $0.01 7/31/2020319,600 shares $4,474.40 +413.0%N/A0 $0.01 7/15/202062,300 shares $1,264.69 -77.0%N/A0 $0.02 6/30/2020270,500 shares $6,951.85 +69.3%N/A0 $0.03 6/15/2020159,800 shares $4,634.20 +1,041.4%N/A0 $0.03 5/29/202014,000 shares $270.20 -94.9%N/A0 $0.02 5/15/2020276,100 shares $5,936.15 +434.0%N/A0 $0.02 4/30/202051,700 shares $1,266.65 +1.0%N/A0 $0.02 4/15/202051,200 shares $1,459.20 +92.5%N/A0 $0.03 3/31/202026,600 shares $798.00 +68.4%N/A0 $0.03 3/13/202015,800 shares $624.10 -78.2%N/A0 $0.04 2/28/202072,300 shares $2,169.00 -58.1%N/A0 $0.03 2/14/2020172,600 shares $8,630.00 +245.9%N/A0 $0.05 1/31/202049,900 shares $2,495.00 -77.7%N/A0 $0.05 1/15/2020224,000 shares $11,244.80 +215.5%N/A0 $0.05 12/31/201971,000 shares $3,550.00 -54.3%N/A0 $0.05 PMCB Short Interest - Frequently Asked Questions What is PharmaCyte Biotech's current short interest? Short interest is the volume of PharmaCyte Biotech shares that have been sold short but have not yet been closed out or covered. As of October 15th, traders have sold 21,100 shares of PMCB short. 0.30% of PharmaCyte Biotech's shares are currently sold short. Learn More on PharmaCyte Biotech's current short interest. What is a good short interest ratio for PharmaCyte Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PMCB shares currently have a short interest ratio of 1.0. Learn More on PharmaCyte Biotech's short interest ratio. What is a good short interest percentage for PharmaCyte Biotech? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.30% of PharmaCyte Biotech's floating shares are currently sold short. Is PharmaCyte Biotech's short interest increasing or decreasing? PharmaCyte Biotech saw a increase in short interest in October. As of October 15th, there was short interest totaling 21,100 shares, an increase of 13.4% from the previous total of 18,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is PharmaCyte Biotech's float size? PharmaCyte Biotech currently has issued a total of 7,679,000 shares. Some of PharmaCyte Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. PharmaCyte Biotech currently has a public float of 7,080,000 shares. How does PharmaCyte Biotech's short interest compare to its competitors? 0.30% of PharmaCyte Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to PharmaCyte Biotech: Kronos Bio, Inc. (1.71%), Precision BioSciences, Inc. (5.77%), Immuneering Co. (7.24%), Barinthus Biotherapeutics plc (0.01%), Monopar Therapeutics Inc. (2.84%), Theratechnologies Inc. (0.18%), Actinium Pharmaceuticals, Inc. (7.22%), Kezar Life Sciences, Inc. (1.63%), Evoke Pharma, Inc. (3.46%), SCYNEXIS, Inc. (2.55%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short PharmaCyte Biotech stock? Short selling PMCB is an investing strategy that aims to generate trading profit from PharmaCyte Biotech as its price is falling. PMCB shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against PharmaCyte Biotech? A short squeeze for PharmaCyte Biotech occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PMCB, which in turn drives the price of the stock up even further. How often is PharmaCyte Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PMCB, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies Kronos Bio Short Squeeze Precision BioSciences Short Squeeze Immuneering Short Squeeze Barinthus Biotherapeutics Short Squeeze Monopar Therapeutics Short Squeeze Theratechnologies Short Squeeze Actinium Pharmaceuticals Short Squeeze Kezar Life Sciences Short Squeeze Evoke Pharma Short Squeeze SCYNEXIS Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PMCB) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.